More than 1.2 million people worldwide were diagnosed with blood cancer in 2020. Accurately identifying molecular alterations within the extensively heterogeneous landscape of blood cancer disorders can contribute to improved prognosis and disease management.
SOPHiA DDM for Blood Cancers is a comprehensive portfolio offering a range of different ready-to-use solutions for a streamlined analysis of blood cancers.
Dont’ miss the exclusive panel discussion of June 17th on “New Variants Detection and Tracking” of COVID-19, featuring our Chief Scientific Officer, and discover how we can play a part in the surveillance of the virus on a global scale.
On June 14th, we’ll be hosting a live corporate satellite session, “Focusing on what matters most: streamlined secondary and tertiary analyses for clinical exome sequencing” as part of the ESHG 2021 meeting, featuring some of our users.
“At SOPHiA GENETICS, the way we work is simple: we focus on the finish line. When you know you can contribute to something greater than yourself that can benefit other people, that’s when you can thrive to be at your best level.”
Webinar: Consolidated approach for the interpretation of hereditary cancer variants
The information included in this document has been prepared for and is intended for viewing by a global audience. This document contains information about products and services which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indication for use. Please consult local sales representative.